Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects

NCT04770610 is registered in ClinicalTrials.gov with Ocumension (Hong Kong) Limited as lead sponsor.

NCT NCT04770610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04770610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects
Lead sponsor
Ocumension (Hong Kong) Limited
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 1, 2021
Completion date
April 30, 2027
Enrollment
678 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

myopia, progressive